These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 34696203)

  • 1. The Epidemiological and Economic Impact of a Cell-Based Quadrivalent Influenza Vaccine in Adults in the US: A Dynamic Modeling Approach.
    Nguyen VH; Hilsky Y; Mould-Quevedo J
    Vaccines (Basel); 2021 Sep; 9(10):. PubMed ID: 34696203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of the cell-based quadrivalent versus the standard egg-based quadrivalent influenza vaccine in Germany.
    Cai R; Gerlier L; Eichner M; Schwehm M; Rajaram S; Mould-Quevedo J; Lamotte M
    J Med Econ; 2021; 24(1):490-501. PubMed ID: 33761803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A real-world study evaluating the relative vaccine effectiveness of a cell-based quadrivalent influenza vaccine compared to egg-based quadrivalent influenza vaccine in the US during the 2017-18 influenza season.
    Divino V; Krishnarajah G; Pelton SI; Mould-Quevedo J; Anupindi VR; DeKoven M; Postma MJ
    Vaccine; 2020 Sep; 38(40):6334-6343. PubMed ID: 32739119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness Analysis of Cell Versus Egg-Based Seasonal Influenza Vaccination in Children and Adults in Argentina.
    Urueña A; Micone P; Magneres MC; McGovern I; Mould-Quevedo J; Sarmento TTR; Giglio N
    Vaccines (Basel); 2022 Sep; 10(10):. PubMed ID: 36298493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimated cost-effectiveness and burden of disease associated with quadrivalent cell-based and egg-based influenza vaccines in Spain.
    Ruiz-Aragón J; Gani R; Márquez S; Alvarez P
    Hum Vaccin Immunother; 2020 Sep; 16(9):2238-2244. PubMed ID: 32040379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelling the Economic Impact of lnfluenza Vaccine Programs with the Cell-Based Quadrivalent Influenza Vaccine and Adjuvanted Trivalent Influenza Vaccine in Canada.
    Nguyen VH; Roy B
    Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and Economic Outcomes Associated with Cell-Based Quadrivalent Influenza Vaccine vs. Standard-Dose Egg-Based Quadrivalent Influenza Vaccines during the 2018-19 Influenza Season in the United States.
    Krishnarajah G; Divino V; Postma MJ; Pelton SI; Anupindi VR; DeKoven M; Mould-Quevedo J
    Vaccines (Basel); 2021 Jan; 9(2):. PubMed ID: 33498724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Economic Evaluation of the Adjuvanted Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in the Spanish Older Adult Population.
    Fochesato A; Sottile S; Pugliese A; Márquez-Peláez S; Toro-Diaz H; Gani R; Alvarez P; Ruiz-Aragón J
    Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of seasonal quadrivalent versus trivalent influenza vaccination in the United States: A dynamic transmission modeling approach.
    Brogan AJ; Talbird SE; Davis AE; Thommes EW; Meier G
    Hum Vaccin Immunother; 2017 Mar; 13(3):533-542. PubMed ID: 27780425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Dynamic Model for Health Economic Analysis of Influenza Vaccination in the Elderly.
    Mullikin M; Tan L; Jansen JP; Van Ranst M; Farkas N; Petri E
    Infect Dis Ther; 2015 Dec; 4(4):459-87. PubMed ID: 26350238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Cost-Effectiveness of Expanding Vaccination with a Cell-Based Influenza Vaccine to Low Risk Adults Aged 50 to 64 Years in the United Kingdom.
    Kohli MA; Maschio M; Mould-Quevedo JF; Ashraf M; Drummond MF; Weinstein MC
    Vaccines (Basel); 2021 Jun; 9(6):. PubMed ID: 34199912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model.
    Crépey P; Boiron L; Araujo RR; Lopez JG; Petitjean A; de Albuquerque Luna EJ
    BMC Public Health; 2020 Sep; 20(1):1374. PubMed ID: 32907562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina.
    Urueña A; Micone P; Magneres C; Mould-Quevedo J; Giglio N
    Vaccines (Basel); 2021 Apr; 9(4):. PubMed ID: 33916048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Economic Comparison of Influenza Vaccines Recommended for Use in Eligible Adults under 65 Years in the United Kingdom.
    Maschio M; Kohli MA; Ashraf M; Drummond MF; Weinstein MC; Mould-Quevedo JF
    Vaccines (Basel); 2022 Apr; 10(4):. PubMed ID: 35455348
    [No Abstract]   [Full Text] [Related]  

  • 15. Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax
    Lamb YN
    Drugs; 2019 Aug; 79(12):1337-1348. PubMed ID: 31372959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From trivalent to quadrivalent influenza vaccines: Public health and economic burden for different immunization strategies in Spain.
    Crépey P; Redondo E; Díez-Domingo J; Ortiz de Lejarazu R; Martinón-Torres F; Gil de Miguel Á; López-Belmonte JL; Alvarez FP; Bricout H; Solozabal M
    PLoS One; 2020; 15(5):e0233526. PubMed ID: 32437476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in the United States.
    de Boer PT; Crépey P; Pitman RJ; Macabeo B; Chit A; Postma MJ
    Value Health; 2016 Dec; 19(8):964-975. PubMed ID: 27987647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Pediatric Influenza Vaccination in The Netherlands.
    de Boer PT; Nagy L; Dolk FCK; Wilschut JC; Pitman R; Postma MJ
    Value Health; 2021 Jan; 24(1):19-31. PubMed ID: 33431149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany.
    Kohli MA; Maschio M; Cartier S; Mould-Quevedo J; Fricke FU
    Vaccines (Basel); 2022 Aug; 10(9):. PubMed ID: 36146464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Public health and economic impact of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Mexico.
    Ruiz-Palacios GM; Beigel JH; Guerrero ML; Bellier L; Tamayo R; Cervantes P; Alvarez FP; Galindo-Fraga A; Aguilar-Ituarte F; Lopez JG
    Hum Vaccin Immunother; 2020 Apr; 16(4):827-835. PubMed ID: 31851570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.